Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

jesmond bioscience gesmbh - cifenotrina; praletrina - solução para pulverização

União Europeia - português - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 e 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

União Europeia - português - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoríase - imunossupressores - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

União Europeia - português - EMA (European Medicines Agency)

mylan s.a.s - a ribavirina - hepatite c, crônica - antivirais para uso sistêmico - a ribavirina mylan é indicada para o tratamento da hepatite c crónica e só deve ser utilizada como parte de um regime combinado com interferão alfa-2b (adultos, crianças (três anos de idade e mais) e adolescentes). a monoterapia com ribavirina não deve ser utilizada. não há informações de segurança ou eficácia sobre o uso de ribavirina com outras formas de interferão (i. não alfa-2b). por favor, consulte também o interferon alfa-2b resumo das características do medicamento (rcm) para a prescrição de informação específico do produto. ingênua patientsadult patientsribavirin mylan é indicado, em combinação com o interferão alfa-2b, para o tratamento de pacientes adultos com todos os tipos de hepatite crônica c, exceto o genótipo 1, não tratados previamente, sem descompensação hepática, com níveis elevados de alanina aminotransferase (alt), que são positivos para hepatite soro-vírus-c (vhc) rna. crianças e adolescentsribavirin mylan é indicado, em uma combinação de tratamento com interferon alfa-2b, para o tratamento de crianças e adolescentes de três anos de idade e mais velhos, que têm todos os tipos de hepatite crônica c, exceto o genótipo 1, não tratados previamente, sem descompensação hepática, e que são soro positivo para hcv rna. quando tomar a decisão de não adiar o tratamento até a idade adulta, é importante considerar que a terapia de combinação induziu uma inibição do crescimento. a reversibilidade da inibição do crescimento é incerto. a decisão de tratamento deve ser feita caso-a-caso (ver secção 4,. anteriormente tratamento de falha de patientsadult patientsribavirin mylan é indicado, em combinação com o interferão alfa-2b, para o tratamento de doentes adultos com hepatite c crónica, que já respondeu (com normalização da alt no final do tratamento), o interferão-alfa monoterapia, mas que, posteriormente, teve recaídas.

União Europeia - português - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imunossupressores - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. o tratamento de graves, ativa e progressiva, a artrite reumatóide em adultos não previamente tratados com metotrexato. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita reduz a taxa de progressão do dano articular, como medido por raio-x e melhora a função física, quando administrado em combinação com metotrexato. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita pode ser administrado como monoterapia em caso de intolerância ao metotrexato ou quando a continuidade do tratamento com metotrexato é inadequada (para a eficácia em monoterapia consulte a secção 5. adalimumab não foi estudado em pacientes com idade inferior a 2 anos. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita reduz a taxa de progressão das lesões das articulações periféricas, conforme medido pelo raio-x em pacientes com poliarticular simétrica subtipos da doença (consulte a secção 5. 1) e melhora a função física. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 e 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

União Europeia - português - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatite, atopic - outras preparações dermatológicas - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. ocorrência de quatro ou mais vezes por ano), que tiveram uma resposta inicial a um máximo de seis semanas de tratamento duas vezes ao dia, pomada de tacrolimus (lesões limpo, quase limpo ou levemente afetados).

União Europeia - português - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrite, reumatóide - imunossupressores - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

União Europeia - português - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - acromegalia - hormonas e análises pituitárias e hipotalâmicas - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

União Europeia - português - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazole - schizophrenia; bipolar disorder - psicolepticos - abilify é indicado para o tratamento da esquizofrenia em adultos e em adolescentes de 15 anos ou mais. abilify é indicado para o tratamento de moderados a graves episódios maníacos em transtorno bipolar i e para a prevenção de um novo episódio de mania em adultos que sofreram predominantemente episódios maníacos e cujos episódios maníacos respondeu ao aripiprazol tratamento. abilify é indicado para o tratamento de até 12 semanas de moderados a graves episódios maníacos em transtorno bipolar i em adolescentes com idade de 13 anos e mais velhos.